FierceBiotech 2026-02-03 Pfizer CEO says pipeline pruning is mostly finished after 6 more early-stage culls, $4.4B in impairment charges
FierceBiotech 2026-02-03 Fledgling biotech Exxel plans $13M IPO to succeed where other FAAH inhibitors have failed
FierceBiotech 2026-02-03 FDA signals tailored approach to ‘carefully shepherd’ CAR-T therapy for autoimmune diseases
FierceBiotech 2026-02-03 Pfizer's $10B monthly GLP-1 bet generates competitive weight loss in phase 2b
FierceBiotech 2026-02-03 NMD flunks rare disease trial but flexes secondary data to accelerate program
FierceBiotech 2026-02-02 Early-stage investor Santé Ventures gins up $330M to spread across biotech, medtech and digital health
FierceBiotech 2026-02-02 China's Newsoara pens $135M deal for remaining rights to vTv's inflammation drug
FierceBiotech 2026-02-02 Daiichi stops internal development of next-wave ADC as key Datroway readout delayed again
FierceBiotech 2026-02-02 Sanofi's troubled GCS inhibitor fails phase 3 Fabry trial but scores in Gaucher disease
FierceBiotech 2026-02-02 AstraZeneca study finds 22 genes tied to chronic disease risk after Epstein-Barr infection